Logo

MHUA

Meihua International Medical Technologies Co., Ltd.

MHUA

Meihua International Medical Technologies Co., Ltd. • NASDAQ
$11.88 ▲ 1.89% (+0.22)
Market Cap $3.76 M
52w High $67.70
52w Low $10.26
Dividend Yield 0%
P/E 0.38
Volume 3.33K
Outstanding Shares 316.73K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $37.982M ▼ $9.373M ▼ $3.145M ▼ 8.28% ▼ $9.86 ▼ $3.514M ▼
Q4-2024 $51.566M ▲ $9.608M ▲ $6.127M ▲ 11.882% ▲ $21 ▲ $9.397M ▲
Q2-2024 $45.344M ▼ $9.243M ▼ $4.717M ▲ 10.402% ▲ $17 ▼ $6.183M ▲
Q4-2023 $48.909M ▲ $10.412M ▲ $4.563M ▼ 9.33% ▼ $19.06 ▼ $5.751M ▼
Q2-2023 $48.19M $8.003M $7.062M 14.654% $30 $9.528M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $15.548M ▼ $190.584M ▲ $25.639M ▼ $164.945M ▲
Q4-2024 $15.96M ▼ $186.239M ▲ $27.264M ▼ $158.976M ▲
Q2-2024 $18.491M ▲ $179.163M ▲ $29.59M ▲ $149.572M ▲
Q4-2023 $16.927M ▼ $171.915M ▲ $25.077M ▲ $146.332M ▲
Q2-2023 $17.861M $162.612M $23.222M $138.891M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $3.145M ▼ $-19.805M ▼ $12.177M ▲ $6.618M ▲ $-386.49K ▼ $-9.913M ▼
Q4-2024 $6.127M ▲ $13.621M ▲ $-14.996M ▼ $79.43K ▼ $0 ▼ $13.498M ▲
Q2-2024 $4.717M ▲ $1.016M ▼ $-5.425M ▲ $6.134M ▲ $781.879K ▲ $1.005M ▼
Q4-2023 $4.563M ▼ $7.7M ▲ $-8.593M ▼ $-15.552K ▼ $-467.167K ▲ $7.52M ▲
Q2-2023 $7.062M $-5.425M $-3.866M $721.677K $-8.875M $-10.008M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been fairly steady over the past few years, inching up but not showing a sharp growth curve. The company has remained consistently profitable, with gross profit and operating profit holding at similar levels over time. Earnings per share have been a bit uneven, with stronger results a few years ago, a dip, and then a partial recovery. Overall, this looks like a business with stable but modest profitability, not a hyper‑growth story. Margins appear reasonable for a traditional disposable medical products maker, but there is no obvious step‑change yet from the newer, higher‑tech initiatives.

Balance Sheet

Balance Sheet The balance sheet looks relatively solid and conservative. Total assets and shareholders’ equity have been building over time, which points to gradual strengthening of the company’s financial base. Cash levels are modest but improving, and debt remains quite low, suggesting limited reliance on borrowing so far. This gives the company some flexibility as it invests in new technology, although the cash cushion does not appear abundant, so large projects will need to be managed carefully.

Cash Flow

Cash Flow Operating cash flow has been generally positive over the five‑year period, but it has fluctuated, with at least one year of outflow. Free cash flow follows the same pattern: usually positive, but not consistently so. Capital spending has been relatively light most years, which fits with a traditional disposable‑product manufacturer that does not require extremely heavy investment in equipment. As the company pushes deeper into robotics, AI platforms, and its Hainan technology park, cash flow volatility could increase if investment ramps up faster than cash generation.

Competitive Edge

Competitive Edge Meihua’s core strength is its broad, “one‑stop” catalog of disposable medical products, serving hospitals and pharmacies with a very wide range of items. This simplifies purchasing for customers and can create stickiness in relationships. Its location in a major medical device manufacturing hub in China further supports low costs and easy sourcing. The company also benefits from scale, automation, and a well‑developed distribution network reaching both domestic and international markets. These factors together form a respectable moat in the traditional disposables segment. However, the disposable medical supply market is highly competitive and price sensitive. As Meihua moves into higher‑tech areas, it will increasingly face competition from larger, more established global med‑tech players, so sustaining a strong position there will require flawless execution and continuous innovation.

Innovation and R&D

Innovation and R&D Innovation is becoming central to Meihua’s story. The company is moving beyond basic disposables into AI‑enabled logistics (“Speed Fox”), high‑precision surgical support systems, and early participation in remote robotic surgery. These initiatives, if scaled successfully, could shift the company toward higher‑margin, more differentiated products and services. The planned medical industrial park in Hainan and the development of robotic‑assisted surgery systems show a clear intent to climb the value chain. Collaboration with universities and medical institutions, plus a growing R&D budget and team, point to a structured innovation pipeline rather than ad‑hoc projects. At the same time, these moves introduce higher technical, regulatory, and commercialization risks. Turning prototypes and pilot projects into reliable, widely adopted products often takes longer and costs more than expected, so there is meaningful uncertainty around timing and ultimate impact on profits.

Summary

Overall, Meihua looks like a stable, modestly profitable disposable medical device business that is trying to reinvent itself as a higher‑tech healthcare technology player. The legacy business provides a broad base of products, cost advantages, and a diversified clientele, which together help support steady revenue and ongoing profitability. The balance sheet is reasonably strong with low debt, and cash flows, while not perfectly consistent, have generally covered the company’s needs so far. The real swing factor is the strategic pivot into AI platforms, robotic‑assisted surgery, and the Hainan technology park. These initiatives create meaningful growth and margin potential but also raise execution and investment risk. People following the company may want to watch how quickly high‑end products ramp, how the revenue mix shifts, and whether profitability and cash generation keep pace with the new ambitions.

NEWS

November 19, 2025 · 4:05 PM UTC

Meihua International Announces 1-For-100 Reverse Share Split

Read more